Lung Biopsy Systems Market

Lung Biopsy Systems Market Snapshot

The global lung biopsy systems market size is expected to reach US$ 8.6 Billion in 2032 and exhibit growth at a CAGR of 9.4% in the forecast period from 2022 to 2032. Demand for lung biopsy systems is anticipated to grow at a rapid pace in future years owing to the surging preference for minimally invasive surgeries. As per FMI, the lung biopsy systems market is likely to be valued at US$ 3.1 Billion in 2022.

Biopsy is considered to be a medical procedure for surgically removing tissues from an organ to evaluate the extent or presence of a disease, especially inflammatory and cancerous conditions. Lung biopsies include the removal of lung tissues for determining any lung disease, infection, or cancer.

Sales of lung biopsy devices are expected to surge in future years backed by increasing initiatives taken by governments to create awareness about cancer. Many global health organizations are also anticipated to provide funds for the enhancement of the reimbursement scenario.

Lung biopsy is often performed either by closed lung or open lung procedures. Closed lung biopsy makes use of a needle, whereas open lung biopsy is performed under general anesthesia in operating rooms by making an incision on the chest or in the skin.

The ability of lung biopsies to help healthcare professionals in correctly diagnosing the suitable treatment for patients is another vital factor that is anticipated to bode well for the lung biopsy systems market size. Besides, increasing health expenditure and rising disposable income of people worldwide are set to aid growth.

How Are Cancer Cases Pushing the Lung Biopsy Systems Market Growth

The increasing prevalence of lung cancer across the globe is estimated to bode well for the lung biopsy systems market growth. According to the World Health Organization (WHO), in 2020, nearly 10 million deaths occurred globally due to cancer. Out of this, lung cancer led to about 1.80 million deaths and 2.21 million new cases were reported the same year. These numbers are expected to surge at a rapid pace, thereby pushing market growth.

Rising smoking habits, lack of physical activities, low fruit and vegetable consumption, increasing alcohol consumption, and high body mass index are expected to bolster the prevalence of cancer and propel this market. In addition to that, increasing support by regulatory bodies in terms of finances to accelerate the development of healthcare infrastructure is likely to boost growth.

Which Factors May Hinder the Lung Biopsy Systems Market Growth

Numerous patient safety risks related to biopsy systems can lead to product recalls. Product recalls may disturb a brand’s image and decline sales of lung biopsy systems in the evaluation period. Also, the high risk of infections associated with these systems may obstruct growth.

Why Are Longer Hospital Stays Driving the North America Lung Biopsy Systems Market

North America is expected to remain at the forefront by generating the largest lung biopsy systems market share in the upcoming years. The presence of numerous leading companies in the U.S. and the rising patient pool in Canada are anticipated to drive the regional market.

The high penetration rate of state-of-the-art devices and the presence of a well-established healthcare system across North America are a couple of other factors that would foster the market. Increasing hospital stay because of lung cancer is another vital growth driver. The availability of sophisticated equipment and facilities for timely diagnosis to reduce the duration of hospital stay is likely to bode well for the market.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How Are Insurance Companies Spurring the Asia Pacific Lung Biopsy Systems Market

Asia Pacific is projected to remain in the second position, followed by North America in the assessment period. The rising aging population prone to lung cancer across developing countries, such as India and China is likely to propel the demand for lung biopsy systems in Asia Pacific.

As per the India Brand Equity Foundation (IBEF), in 2022, the Indian healthcare sector is estimated to reach US$ 372 billion. The penetration of health insurance is set to expand in future owing to the high demand for quality and cost-effective healthcare. The rising number of various insurance companies in this country providing coverage of cancer treatment is a major factor that is set to augment the Asia Pacific market.

Market Competition

Some of the reputed companies in the global lung biopsy systems market include Fujifilm Medical Systems, DTR Medical, BD, Olympus Corporation, Medtronic, Hologic, Inc., B. Braun Melsungen AG, Cardinal Health, and Argon Medical Devices among others.

The global market is highly competitive with the presence of a large number of big and small-scale enterprises. The majority of these enterprises are increasingly focusing on technological collaborations and acquisitions to gain a competitive edge in the market. Meanwhile, a few other key players are striving to broaden their product portfolios by launching cutting-edge devices in the market.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Report Scope

Key Segments Profiled in the Lung Biopsy Systems Industry Survey

By Product Type:

• Core Needle Biopsy Devices
• Fine Needle Aspiration Biopsy Devices
• Surgical Biopsy Devices
• Vacuum-Assisted Biopsy Devices

By Procedure Type:

• Needle Biopsy
• Thoracoscopic Biopsy
• Transbronchial Biopsy
• Open Biopsy

By End Use:

• Hospitals
• Cancer Research Centers
• Specialty Clinics
• Others

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• Japan
• Middle East and Africa